Updated:
Plus Therapeutics
Plus Therapeutics repurposes radiopharmaceutical Rhenium-186 NanoLiposome to target recurrent glioblastoma and leptomeningeal metastases.
Plus Therapeutics
Plus Therapeutics was founded in 2015 as a restructuring of Cytori Therapeutics, with Marc Hedrick, a plastic surgeon and veteran of the regenerative medicine sector, taking the helm as CEO. The company emerged from a reverse merger and a strategic pivot, shedding its prior focus on cell therapy to concentrate exclusively on oncology. It incorporates as a clinical-stage biotech rather than a traditional investment firm, but its function — allocating institutional capital, managing risk across a portfolio of drug candidates, and seeking regulatory milestones — mirrors that of a life-sciences asset manager operating its own pipeline. The firm's lead asset is Rhenium-186 NanoLiposome, a radiopharmaceutical designed to deliver targeted beta radiation directly into solid tumors via convection-enhanced delivery. Its therapeutic strategy focuses on recurrent glioblastoma, a uniformly fatal brain cancer with almost no durable treatment options, and leptomeningeal metastases, where cancer spreads to the cerebrospinal fluid. Plus Therapeutics secured a $17.6 million Product Development Research agreement with the Cancer Prevention and Research Institute of Texas in 2021 and expanded that support with a larger follow-on award of $33.1 million in 2024 (per the firm's public disclosures). The National Cancer Institute also enrolled the company's asset in its NExT Program to support manufacturing scale-up. The company operates out of Austin, Texas, and maintains clinical trial sites at major cancer centers including the University of Texas MD Anderson Cancer Center and the University of Texas Health Science Center at San Antonio. As a micro-cap public company trading on Nasdaq, its scale is limited — market capitalization ranged under $15 million through mid-2024 — with capital deployment governed by Phase 1 and Phase 2 clinical trial costs rather than an investment committee allocating to external managers. February 2024: Plus Therapeutics reported positive interim data from its ReSPECT-LM trial, showing a median overall survival of 11 months in patients with leptomeningeal metastases, a population that historically averages 2-5 months (per the firm's corporate presentation, 2024). Plus Therapeutics occupies a distinct niche: it is a single-asset clinical-stage biotech whose central technical insight is not a new molecule but a new use for an established isotope, repurposing a supply chain that already exists. Its structural differentiator is this regulatory and manufacturing pathway — seeking FDA approval by demonstrating safety and efficacy improvements in administration and targeting, rather than by inventing a novel compound. Succession risk is concentrated in Hedrick, who has served as CEO since the 2019 merger and personally shapes trial design and investor communication.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Austin
Corporate office
Austin, TX, United States
Principals
Marc H. Hedrick
President and Chief Executive Officer
Sector focus
Frequently asked questions
Does Plus Therapeutics operate as a family office or an asset manager?
Plus Therapeutics is a publicly traded, clinical-stage biotech company — not a family office, not a fund manager. Its capital deployment mirrors an asset manager's in that it allocates cash and grant funding across a narrow portfolio of oncology candidates, but it does not manage third-party LP capital or charge management fees. External allocators encounter it as a potential public-equity investment or a co-development partner, not as a fund.
Who controls capital allocation decisions at Plus Therapeutics?
Marc Hedrick, President and CEO, is the key decision-maker. He has led the company since the 2019 Cytori merger and directs trial-design choices, grant applications, and public-market communications. The board of directors approves major financing events, but operational allocation runs through Hedrick.
What is Rhenium-186 NanoLiposome, and why is it the only notable clinical asset?
Rhenium-186 NanoLiposome is a radiopharmaceutical that encapsulates the isotope Rhenium-186 in a liposomal carrier, injected directly into the tumor site. It seeks to solve the delivery problem that has limited radiation therapy for brain cancers. Plus Therapeutics is effectively a single-asset company; if the ReSPECT trials fail to produce a registrational data package, the firm has no backup candidate close to the clinic.
How does the company fund its clinical trials?
Trial funding comes from a mix of equity issuances on Nasdaq and non-dilutive grant funding, most notably a series of awards from the Cancer Prevention and Research Institute of Texas. A $33.1 million grant extension from CPRIT in 2024 is the dominant source of near-term clinical capital, alongside a research collaboration with the NCI's NExT Program for manufacturing scale-up.
What cancers does Plus Therapeutics target, and why these?
Recurrent glioblastoma and leptomeningeal metastases are the two primary indications. Both are central nervous system cancers with negligible competition from existing radiopharmaceuticals and a clear unmet need — median survival is measured in months. The firm's thesis is that convection-enhanced delivery of Rhenium-186 can achieve tumor-killing radiation doses that external-beam radiation or systemic chemotherapy cannot reach.
What is the known posture on external co-investment or partnerships?
Plus Therapeutics does not participate in fund commitments or club deals. Its external engagement model is a classic biotech partnership: it seeks academic collaborators for clinical trial enrollment, grant agencies for non-dilutive cash, and larger pharmaceutical companies as potential acquirers or licensors once human proof-of-concept data matures. There is no LP structure, no co-investment vehicle.
What is the succession risk if Marc Hedrick departs?
Hedrick is the founder-CEO and principal architect of the Cytori-to-Plus reverse-merger strategy. No named successor has been disclosed, and the company's board is small. In a micro-cap biotech with a single clinical asset, key-man risk is material: any abrupt departure would likely trigger capital-markets uncertainty and operational delays while a new clinical lead is recruited.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: